ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HART NYLI Healthy Hearts ETF

31.1642
0.0642 (0.21%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
NYLI Healthy Hearts ETF AMEX:HART AMEX Exchange Traded Fund
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.0642 0.21% 31.1642 31.1642 31.13 31.13 23 18:02:57

Current Report Filing (8-k)

10/04/2023 2:30pm

Edgar (US Regulatory)


0001563665 false 0001563665 2023-04-05 2023-04-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 5, 2023

 

BIOSTAGE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35853   45-5210462

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

84 October Hill Road, Suite 11, Holliston, MA   01746
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (774) 233-7300

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 5, 2023, Ron Packard, the Chief Executive officer of Pansophic Learning, joined the Board of Directors (the “Board”) of the Company as a Class II director. The appointment to the Board was effective immediately. As a Class II director, the initial term of Mr. Packard as director will run until the Company’s 2024 annual meeting of stockholders and until his successor is duly elected and qualified, or until his resignation or removal.

 

In connection with his appointment, the Company will grant Mr. Packard, on the fifth business day following his appointment, stock options with a value of $25,000 at the grant date that will vest in full in equal quarterly increments over a period of one year from the grant date. In addition, for his service, Mr. Packard will receive compensation commensurate with that received by the Company’s other non-employee directors, which as may be modified by the Board from to time, currently includes annual compensation of cash fees of $20,000 to be paid in quarterly increments, and an annual grant of stock options, granted on the fifth business day following the Corporation’s annual stockholders meeting, with a value of $25,000 at the grant date to vest in full in equal quarterly increments over a period of one year from the grant date. In addition, all non-employee directors shall be reimbursed for their expenses incurred in connection with attending Board and committee meetings.

 

Mr. Packard does not have any family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or officer.

 

On April 10, 2023, the Company issued a press release regarding the appointment of Mr. Packard and related matters. The full text of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

  Title
99.1   Press Release issued by Biostage, Inc. on April 10, 2023
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

2
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BIOSTAGE, INC.
    (Registrant)
     
April 10, 2023   /s/ Joseph Damasio
(Date)   Joseph Damasio
    Chief Financial Officer

 

3

1 Year NYLI Healthy Hearts ETF Chart

1 Year NYLI Healthy Hearts ETF Chart

1 Month NYLI Healthy Hearts ETF Chart

1 Month NYLI Healthy Hearts ETF Chart

Your Recent History

Delayed Upgrade Clock